Medicine and Dentistry
Radiation Therapy
100%
Neoplasm
46%
Hodgkin's Lymphoma
38%
Brentuximab Vedotin
33%
Radioimmunotherapy
26%
Non-Hodgkin Lymphoma
19%
Overall Survival
18%
Immunotherapy
16%
Diseases
15%
Anaplastic Large Cell Lymphoma
13%
Follicular Lymphoma
12%
Peripheral T-Cell Lymphoma
12%
Rituximab
12%
Ibritumomab Tiuxetan
11%
Progression Free Survival
11%
CHOP
10%
Adverse Event
10%
Tumor Cell
10%
ABVD
9%
Hypoxia
9%
Cutaneous T Cell Lymphoma
9%
Immune Response
9%
Muscle Invasive Bladder Cancer
8%
Programmed Cell Death
8%
Systemic Therapy
7%
Positron Emission Tomography
7%
Tumor Microenvironment
7%
Monoclonal Antibody
7%
B-Cell Lymphoma
6%
Bladder Cancer
6%
Stem Cell Transplant
6%
Autologous Stem Cell Transplantation
6%
Diffuse Large B-Cell Lymphoma
6%
Yttrium 90
6%
Programmed Death-Ligand 1
6%
Iodine 131
6%
Breast Cancer
6%
Noninferiority Trial
6%
Lymphocyte
6%
Oropharyngeal Cancer
6%
Hazard Ratio
6%
Immune Checkpoint Inhibitor
5%
Doxorubicin
5%
Metaphase
5%
Cancer Research
5%
Programmed Death 1 Ligand 1
5%
Malignant Neoplasm
5%
Positron Emission Tomography-Computed Tomography
5%
Hematologic Malignancy
5%
Solid Malignant Neoplasm
5%
Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
36%
Neoplasm
35%
Brentuximab Vedotin
27%
Chemotherapy
26%
Malignant Neoplasm
20%
Anaplastic Large Cell Lymphoma
16%
Monoclonal Antibody
15%
Hodgkin Disease
14%
Overall Survival
14%
Progression Free Survival
14%
Immunotherapy
12%
Cutaneous T Cell Lymphoma
12%
Disease
12%
Remission
12%
Nonhodgkin Lymphoma
11%
B Cell Lymphoma
11%
Yttrium 90
10%
Toll Like Receptor 7
9%
Follicular Lymphoma
9%
Ibritumomab Tiuxetan
9%
Peripheral T Cell Lymphoma
9%
Obinutuzumab
9%
Iodine-131
8%
Cyclophosphamide
7%
Hematologic Malignancy
7%
Combination Therapy
6%
Diffuse Large B Cell Lymphoma
6%
Tumor Model
6%
Adverse Event
6%
Solid Malignant Neoplasm
6%
Immunoglobulin
5%
Mouse
5%
Immunology and Microbiology
Immunotherapy
31%
Immune Response
20%
T Cell
20%
Monoclonal Antibody
20%
Brentuximab Vedotin
18%
Rituximab
16%
B Cell
15%
Lymphoma Cell
14%
Agonist
14%
Cell Death
13%
Toll-Like Receptor
13%
Mouse
13%
Overall Survival
11%
Tumor Cell
11%
CD20
10%
Programmed Death-Ligand 1
10%
Progression Free Survival
10%
Syngenic
9%
Obinutuzumab
9%
Macrophage
8%
Myeloid
7%
TLR7
7%
Intravenous Immunoglobulin
7%
Positron Emission Tomography
7%
Immunosuppressive Drug
7%
Iodine-131
6%
Caspase
6%
Cyclophosphamide
6%
Monospecific Antibody
6%
Stem Cell Transplant
6%
Lymphocyte Count
6%
Immunosuppression
6%
Natural Killer Cell
5%
Immune System
5%
Programmed Death 1 Ligand 1
5%
Host Immune Response
5%